

## Kidney Cancer Advisory Committee Interests Register

**Register last updated: 09/12/25.**

**All interests signed off by the Chair Guideline Lead and Associate Director**

Name	Role on the committee	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Baljit Singh	Committee member – Chair	Direct-financial	I am a clinical advisor for the insurance company WPA. I only deal with claims for colorectal surgery.	07/22	05/23	Ongoing	Non-specific Declare and participate.
Baljit Singh	Committee member – Chair	Direct-financial	On the surgical advisory board for Suturion.	01/23	05/23	Ongoing	Non-specific Declare and participate.
Baljit Singh	Committee member – Chair	Direct-financial	Consultant Surgeon and Honorary Associate Professor, Leicester General Hospital	12/03	05/23	Ongoing	Declare and participate. Salaried employment in the NHS.
Baljit Singh	Committee member – Chair	Direct-non-financial professional and personal	I am Chair of the Specialised Colorectal CRG NHS England until June 2023. I was paid 1PA but this ceased in April 2022.	04/19	05/23	06/23	Non-specific Declare and participate.

Baljit Singh	Committee member – Chair	Direct-financial	Vice Chair of NICE TAC (Technology Appraisal Committee) B. I receive 2PA and expenses to travel to face to face meetings.	03/22	05/23	Ongoing	Non-specific Declare and participate.
Baljit Singh	Committee member – Chair	Direct -non- financial professional and personal	I was on the Committee for the Technology Appraisal on Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858).	09/22	08/23	01/23	Specific Declare and participate. Open declaration is sufficient mitigation.
Baljit Singh	Committee member – Chair	Direct -non- financial professional and personal	I am involved in the renal cancer treatment pathway. The first TAC committee meeting is in September 2023.		08/23	Ongoing	Specific Declare and participate. Open declaration is sufficient mitigation.
Baljit Singh	Committee member – Chair	Direct -non- financial professional and personal	Attending a course on surgical techniques for rectal cancer 18-19th June in Milan Italy, this is for educational purposes which was supported by Johnson and Johnson covering travel. No honorarium was paid.	06/24	06/24	06/24	Non-specific Declare and participate.

Baljit Singh	Committee member – Chair	Direct-financial	Honorarium received from Arthrex for running an educational course (laparoscopic cadaveric course 29-30th October 2024).	10/24	01/25	10/24	Non-specific Declare and participate.
Axel Bex	Committee member – Urological Surgeon	Indirect-financial and direct non-financial professional and personal	Restricted educational grant from Pfizer for a neoadjuvant trial on Kidney Cancer, paid to institution.  I am PI of the trial which treated patients with avelumab and axitinib. The trial is closed and has been presented at GU ASCO in 2022.	01/18	10/23	Ongoing	Specific Declare and participate.  Evidence for drug treatments was not reviewed as part of this work and technology appraisals were incorporated without change.
Axel Bex	Committee member – Urological Surgeon	Direct-financial	Speaker on an Ipsen led symposium on the topic of cytoreductive nephrectomy. I received honoraria for this work.	08/23	10/23	10/23	Specific Declare and participate.  Open declaration is sufficient mitigation
Axel Bex	Committee member – Urological Surgeon	Direct, non-financial professional and personal	Chair of the EAU renal cancer guideline panel. Unpaid work and no honoraria. The travel and accommodation are organised by the EAU	08/23	10/23	Ongoing	Non-specific Declare and participate.

			without direct reimbursement.				
Axel Bex	Committee member – Urological Surgeon	Direct, non-financial professional and personal	Medical Steering committee member of the Kidney Cancer Association, a US based patient advocacy group. Unpaid and no honoraria for this role. Travel expenses paid if invited as a speaker to their meetings.	2017	10/23	Ongoing	Non-specific Declare and participate.
Axel Bex	Committee member – Urological Surgeon	Direct, non-financial professional and personal	Medical Steering Committee member of the International Kidney Cancer Coalition (IKCC), an international patient advocacy group. Unpaid and no honoraria nor expenses.	2018	10/23	Ongoing	Non-specific Declare and participate.
Axel Bex	Committee member – Urological Surgeon	Direct, non-financial professional and personal	Steering committee member of an adjuvant trial for kidney cancer led by Roche Genentech.  The work is unpaid, I did not receive honoraria nor expenses as the meetings were attached to international cancer meetings. The trial	2017	10/23	Ongoing	Specific Declare and participate.  Evidence for drug treatments was not reviewed as part of this work and technology appraisals were incorporated without change.

			investigated adjuvant atezolizumab but was negative and will not change practice.				
Axel Bex	Committee member – Urological Surgeon	Direct, non-financial professional and personal	Steering committee member of an adjuvant trial for kidney cancer led by BMS. The work is unpaid, I did not receive honoraria nor expenses as the meetings were attached to international cancer meetings. The trial investigated adjuvant nivolumab and ipilimumab but was negative and will not change practice.	2017	10/23	Ongoing	Specific Declare and participate. Evidence for drug treatments was not reviewed as part of this work and technology appraisals were incorporated without change..
Axel Bex	Committee member – Urological Surgeon	Indirect-financial and direct, non-financial professional and personal	Member of the DSMB of an adjuvant trial for kidney cancer by Merck.  The work was unpaid but honoraria for participation were reimbursed per hour to my previous employer. I am no longer a member of the DSMB.  The trial was the Keynote 564 adjuvant trial investigating	2018	10/23	08/23	Specific Declare and participate.

			pembrolizumab versus placebo.				
Axel Bex	Committee member – Urological Surgeon	Direct-financial	Speaker on an EISAI led symposium during the European Association of Urology (EAU) congress on the topic of cytoreductive nephrectomy. I received a honorarium for this work.	07/22	10/23	07/22	Specific Declare and participate. Open declaration is sufficient mitigation
Axel Bex	Committee member – Urological Surgeon	Direct, non-financial professional and personal	Board member and past Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Unpaid. No honoraria. Travel to meetings in Brussels was reimbursed.	2018	10/23	Ongoing	Specific Declare and participate. Open declaration is sufficient mitigation
Axel Bex	Committee member – Urological Surgeon	Direct-financial	Consultant Clinical Lead, Royal Free London NHS Foundation Trust	12/18	10/23	Ongoing	Declare and participate. Salaried employment in the NHS.
Axel Bex	Committee member – Urological Surgeon	Indirect financial and direct non-financial professional and personal	<a href="#">Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous</a>	07/23	07/24		Specific Declare and participate Study included in the evidence base for RQ3b for completeness however trial

			<a href="#">Cryoablation and Robot-assisted Partial Nephrectomy - PubMed (nih.gov)</a>				is a very small feasibility study and forms a very small part of the evidence base.  (RQ3b looked at non-surgical interventions or active surveillance, compared to each other or surgical interventions, for localised renal cell carcinoma in adults.)
Axel Bex	Committee member – Urological Surgeon	Direct non-financial professional and personal	Member of the National Kidney Cancer Audit Clinical Reference Group.		08/24	Ongoing	Declare and participate Non-specific
Axel Bex	Committee member – Urological Surgeon	Direct non-financial professional and personal	<a href="#">Oza, Bhavna, Eisen, Tim, Frangou, Eleni et al. (2022) External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.</a> Journal of clinical oncology: official journal of the American Society of Clinical Oncology 40(16): 1772-1782	2022	10/24		Specific Declare and partial exclusion  Must be excluded from making recommendations pertaining to the Leibovich tool for RQ2c part 1 (prognostic models for non-metastatic kidney cancer).

							<p>Participate in discussion but withdraw for drafting recommendations.</p> <p><b>Axel Bex, Committee member, was excluded from recommendation drafting about prognostic models for non-metastatic kidney cancer at committee meeting 8 on 12/12/24 and committee meeting 12 (day 2) on 13/06/25 due to a declared conflict of interest, in line with NICE's policy.</b></p>
Axel Bex	Committee member – Urological Surgeon	Direct non-financial professional and personal	<a href="#">Klatte, T., Gallagher, K.M., Afferi, L. <i>et al.</i> The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. <i>BMC Med</i> 17, 182 (2019).</a>	2019	10/24		<p>Specific</p> <p>Declare and partial exclusion</p> <p>Must be excluded from making recommendations pertaining to the VENUSS tool for papillary RCC for RQ2c part 1 (prognostic models for non- metastatic kidney cancer).</p>



							<p>Participate in discussion but withdraw for drafting recommendations.</p> <p><b>Axel Bex, Committee member, was excluded from recommendation drafting about prognostic models for non-metastatic kidney cancer at committee meeting 8 on 12/12/24 and committee meeting 12 (day 2) on 13/06/25 due to a declared conflict of interest, in line with NICE's policy.</b></p>
Axel Bex	Committee member – Urological Surgeon	Direct -non-financial professional and personal	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel P; Powles, Thomas; Van	12/2024	12/2024		<p>Specific</p> <p>Declare and partial exclusion</p> <p>Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.</p>

			Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.); <a href="#">Scandinavian journal of urology; 2019; vol. 53 (no. 1); 14-20</a>				Participate in discussion but withdraw for drafting recommendations.  <b>Axel Bex, Committee member, was excluded from recommendation drafting about follow-up at committee meeting 12 (day 2) on 13/06/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Axel Bex	Committee member – Urological Surgeon	Direct -non-financial professional and personal	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel Paul; Torbrand, Christian; Powles, Thomas; Van Werkhoven, Erik; Meijer,	12/2024	12/2024		Specific  Declare and partial exclusion  Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.

			Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).; <a href="#">European urology; 2019; vol. 75 (no. 2); 261-264</a>				Participate in discussion but withdraw for drafting recommendations.  <b>Axel Bex, Committee member, was excluded from recommendation drafting about follow-up at committee meeting 12 (day 2) on 13/06/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Axel Bex	Committee member – Urological Surgeon	Indirect-financial	Restricted educational grant from Pfizer for a neoadjuvant trial on Kidney Cancer, paid to institution.	01/18	12/24	Ongoing	Declare and participate Interest is non-specific
Axel Bex	Committee member – Urological Surgeon	Direct-financial	Speaker on an Ipsen led symposium on the topic of cytoreductive nephrectomy. Speaker fees received.	08/23	12/24	10/23	Declare and participate Interest is specific to RQ6b but ceased before evidence was reviewed and recommendations made.  (RQ6b looks at non-pharmacological interventions used before or after systemic anti-cancer therapy in adults with previously untreated

							advanced renal cell carcinoma.)
Axel Bex	Committee member – Urological Surgeon	Direct-financial	Participant in a data-analysis project to evaluate Zirconium-girentuximab PET scans for Telix Pharmaceuticals. Speaker fees received.	11/24	12/24	11/24	Declare and participate Interest is non-specific
Axel Bex	Committee member – Urological Surgeon	Direct-non-financial professional and personal	<a href="#">De Bruijn, Roderick Emile, Mulders, Peter, Jewett, Michael A et al. (2019) Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).</a> European urology 76(4): 437-440  <a href="#">Bex, Axel, Mulders, Peter, Jewett, Michael et al. (2019) Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.</a>	2019	03/25		<p>Specific</p> <p>Declare and partial exclusion</p> <p>Study included in the evidence base for RQ6 part 1 however committee member's expertise is essential to this discussion.</p> <p>Participate in discussion but withdraw for drafting recommendations.</p> <p>(RQ6 part 1 looks at non-pharmacological interventions before systemic anti-cancer therapy for previously untreated renal cell carcinoma)</p> <p><b>Axel Bex, Committee member, was excluded from recommendation</b></p>

			JAMA oncology 5(2): 164-170				<b>drafting about non-pharmacological interventions before SACT at committee meeting 10 (day 1) on 20/03/25, committee meeting 12 (day 2) on 13/06/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Axel Bex	Committee member – Urological Surgeon	Direct-non-financial professional and personal	<a href="#">de Groot, Saskia, Redekop, William K, Sleijfer, Stefan et al. (2016) Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.</a> Urology 95: 121-7	2016	03/25		<p>Specific</p> <p>Declare and partial exclusion</p> <p>Study included in the evidence base for RQ6 part 1 however committee member's expertise is essential to this discussion.</p> <p>Participate in discussion but withdraw for drafting recommendations.</p> <p>(RQ6 part 1 looks at non-pharmacological interventions before systemic anti-cancer</p>

							therapy for previously untreated renal cell carcinoma).  <b>Axel Bex, Committee member, was excluded from recommendation drafting about non-pharmacological interventions before SACT at committee meeting 10 (day 1) on 20/03/25, committee meeting 12 (day 2) on 13/06/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Axel Bex	Committee member – Urological Surgeon	Direct-non-financial professional and personal	<a href="#">Fransen van de Putte, Elisabeth E, van den Brink, Luna, Mansour, Mohamed A et al. (2023) Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?.</a> European	2023	03/25		Specific  Declare and partial exclusion  Study included in the evidence base for RQ6 part 2 however committee member's expertise is essential to this discussion.

			urology open science 55: 15-22				<p>Participate in discussion but withdraw for drafting recommendations.</p> <p>(RQ6 part 2 looks at non-pharmacological interventions after systemic anti-cancer therapy for adults with advanced renal cell carcinoma)</p> <p><b>Axel Bex, Committee member, was excluded from recommendation drafting about non-pharmacological interventions after SACT at committee meeting 10 (day 1) on 20/03/25, committee meeting 12 (day 2) on 13/06/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b></p>
Axel Bex	Committee member – Urological Surgeon	Direct non-financial professional and personal	Ranieri, V., Warren, H., Florez, I., Neves, J.B., Walkden, M., Bernstein, D.E., Santiapillai, J., Williams, N., Wildgoose, W.H., Patki, P., Stewart,	2024	04/25		<p>Specific</p> <p>Declare and partial exclusion.</p>

			G.D., Kinsella, N., Pizzo, E., Barod, R., Bex, A., Mumtaz, F., El-Sheikh, S., Gurusamy, K. and Tran, M.G.B. (2024), Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. BJU Int, 134: 796-804. <a href="https://doi.org/10.1111/bju.16470">https://doi.org/10.1111/bju.16470</a>				<p>Included study for RQ1 on information needs.</p> <p>Participate in discussion but withdraw from drafting recommendations about information to be provided about biopsy. Able to draft recommendations on information to be provided at other stages of the treatment pathway.</p> <p><b>Axel Bex, Committee member, was excluded from recommendation drafting about information to be provided about biopsy at committee meeting 11 (day 2) on 08/05/25 due to a declared conflict of interest, in line with NICE's policy.</b></p>
Axel Bex	Committee member – Urological Surgeon	Direct non-financial professional and personal	Co-author: Bernstein DE, Warren H, Santiapillai J, Fox G, Wildgoose WH, Stewart GD, et al. A modified Delphi consensus statement on the role of biopsy in small renal masses. BJUI Compass. 2025; 6(4):e70018. <a href="https://doi.org/10.1002/bco.2.70018">https://doi.org/10.1002/bco.2.70018</a>	03/25	05/25		<p>Specific</p> <p>Declare and participate</p> <p>Interest is specific to RQ2b on biopsy but study was not included in the evidence base.</p>



Janet Brown	Committee member – Medical Oncologist	Direct-financial	Employment as Professor of Translational Medical Oncology, University of Sheffield	10/13	10/23	Ongoing	Declare and participate. Salaried employment in not-for-profit organisation providing NHS services.
Janet Brown	Committee member – Medical Oncologist	Direct-financial	Honorary Consultant, Sheffield Teaching Hospitals	10/13	10/23	Ongoing	Declare and participate. Salaried employment in the NHS.
Janet Brown	Committee member – Medical Oncologist	Direct-financial	Advisory Boards attended/talks given since September 2022.  Bristol, Myers, Squibb  Pfizer  Eisai  Ipsen  No continuous work. Each meeting was a one-off occasion. No continuing contractual agreements. These were related to Kidney Cancer.	 08/23  07/23,  06/23, 04/23  09/23, 05/23, 09/22	10/23	 08/23  07/23,  06/23, 04/23  09/23, 05/23, 09/22	Specific Declare and participate.

Janet Brown	Committee member – Medical Oncologist	Non-financial professional and personal	I have been involved in design of and recruitment to a number of renal cancer trials and been an author on the relevant publications.  Recent papers in which I have presented trial and other evidence related to renal cancer include those listed below.	2011	10/23	Ongoing	Specific  Declare and participate.  Interest will be kept under review depending on the matter under consideration.
Janet Brown	Committee member – Medical Oncologist	Non-financial professional and personal	Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T et al. <a href="#">Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.</a> Lancet Oncol. 2023; 24:213-22..	01/23	10/23	01/23	Specific  Declare and participate.  Evidence for drug treatments was not reviewed as part of this work and technology appraisals were incorporated without change.
Janet Brown	Committee member – Medical Oncologist	Non-financial professional and personal	Diagnosis, treatment, and survival from kidney cancer: real-world National Health Service England data between 2013 and 2019. Conroy S, Catto J, Bex A, Brown J, Cartledge	07/23	10/23	07/23	Specific  Declare and participate.  Interest will be kept under review depending on the matter under consideration.

			J, Fielding A et al. Diagnosis, treatment and survival from kidney cancer: real-world NHS England data between 2013 and 2019. BJU International, 30 <sup>th</sup> July, 2023.				
Janet Brown	Committee member – Medical Oncologist	Non-financial professional and personal	Paper which is in the course of publication:  Vasudev NS, Ainsworth G, Brown S, Lisa Pickering L, Tom Waddell T.....Brown J et al. Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized Phase II trial (PRISM). J Clin Oncol Submitted.		10/23	Ongoing	Specific  Declare and participate.  Interest will be kept under review depending on the matter under consideration.
Lisa Browning	Committee member – Histopathologist	Direct-financial	I am employed as a Consultant Urological Pathologist by Oxford University Hospitals NHS Foundation Trust (OUHFT).	02/10	10/23	Ongoing	Declare and participate.  Salaried employment in the NHS.
Lisa Browning	Committee member – Histopathologist	Direct-financial	I undertake Private Practice for Nuffield Health in Oxford (histopathology	02/10	10/23	Ongoing	Specific

			<p>related to urological specimens).</p> <p>This work covers all urological pathology including kidney cancer cases. I spend &lt;4 hours per week on private practice (&lt;10%).</p>				<p>Declare and participate.</p> <p>Private practice linked to kidney cancer is limited and represents less than 10% of overall practice.</p>
Lisa Browning	Committee member – Histopathologist	Direct-financial and direct-non-financial professional and personal	<p>I am a co-applicant and workstream Lead for Education and Training for the ArticulatePro study (funding - NHSX Artificial Intelligence in Health and Care Award).</p> <p>This is related to Prostate.</p> <p>The payment associated with this role goes into my paid salary via OUHFT.</p>	2022-24	10/23	Ongoing	<p>Non-specific</p> <p>Declare and participate</p>
Lisa Browning	Committee member – Histopathologist	Direct-financial and direct-non-financial professional and personal	<p>I am co-PI for the Oncology workstream of the Oxford-Janssen collaborative project (<a href="#">Cartography-Oncology: a single cell atlas of urological malignancies</a>).</p>	2022/25	10/23	Ongoing	<p>Not specific</p> <p>Declare and participate.</p> <p>Monies form part of salaried employment and paper would not be included in evidence base.</p>

			<p>This project is looking at Kidney cancer and Bladder cancer.</p> <p>The payment associated with this role goes into my paid salary via OUHFT.</p>				
Lisa Browning	Committee member – Histopathologist	Direct-financial and direct-non-financial professional and personal	<p>Regular speaker on kidney cancer at educational events in the UK and on occasion, abroad. These are often events arranged by BAUP (see below) or the BDIAP and I also regularly lecture on renal tumours for the Oxford FRCPATH course. Due to give a session for ISUP in early 2024.</p> <p>Sometimes I receive honoraria – these come from the educational charity BAUP.</p> <p>Expenses are usually paid for speaker expenses – travel and accommodation and sometimes a meal.</p>		10/23	Ongoing	<p>Specific</p> <p>Declare and participate.</p> <p>Reimbursement reasonable in exchange for expertise.</p>
Lisa Browning	Committee member – Histopathologist	Direct, Non-financial	Membership of the working group for the	2022	10/23	Ongoing	<p>Non-specific</p> <p>Declare and participate.</p>

		professional and personal	<a href="#">ICCR renal cancer dataset 2022</a> – current.  I am not paid for this role.				
Lisa Browning	Committee member – Histopathologist	Indirect financial and Direct, non-financial professional and personal	Co-applicant (I am not paid for this work)  CDMRP Kidney Cancer Research Program (Sept 2020-Sept 2023)  Analysis of Transcriptional Profiles During the Evolution of ccRCC From Premalignant to Malignant Lesions  PIs Prof David Mole, Olivia Lombardi	2020	10/23	Ongoing	Non-specific Declare and participate.
Lisa Browning	Committee member – Histopathologist	Indirect financial and Direct, non-financial professional and personal	Co-applicant (I am not paid for this work)  Medical & Life Sciences Translational Fund (MLSTF, Oct 2022-Sept 2023)  Urological Cancer Pathology AI - Beyond Prostate.  PI Prof Clare Verrill	2022	10/23	Ongoing	Non-specific Declare and participation

Lisa Browning	Committee member – Histopathologist	Direct, Non- financial professional and personal	Member of the <a href="#">Renal GeCIP</a> (I am not paid for this role). This is related to Kidney Cancer.	2019	10/23	Ongoing	Specific Declare and participate. Open declaration is sufficient mitigation
Lisa Browning	Committee member – Histopathologist	Direct-financial and direct-non- financial professional and personal	Member of the Oxford group for <a href="#">PathLAKE</a> .  This is related to digital pathology and whilst not specifically related to Kidney cancer I have published on kidney cancer related digital pathology as part of this role.  My salary from PathLAKE was paid into my salary from OUHFT.	2019	10/23	Ongoing	Specific Declare and participate. Open declaration is sufficient mitigation
Lisa Browning	Committee member – Histopathologist	Direct non- financial professional and personal	Member of the National Kidney Cancer Audit Clinical Reference Group.  No payment received or expenses claimed.	08/23	08/24	Ongoing	Non-specific Declare and participate
Lisa Browning	Committee member – Histopathologist	Direct – financial	I am a member of the International Neoadjuvant Kidney Cancer Consortium (INKCC) as a histopathologist	10/24	04/25	Ongoing	Non-specific Declare and participate

			representative. I do not receive any income from INKCC however I do receive reimbursement for travel expenses for attendance at meetings and hotel accommodation and meals are provided.				
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	<p>Speaker Fees: Advanced Accelerator Applications, Astellas, Bayer, BMS, Eisai Ltd, EUSA, Ipsen, Janssen, Novartis, Pfizer, Sanofi.</p> <p>Astellas, AAA, Bayer, Janssen, Sanofi - are prostate related.</p> <p>Eisai Ltd, Novartis, Pfizer, EUSA was kidney cancer related prior to 2023.</p>	2014	09/23	Ongoing	Specific Declare and participate. Relevant interests occurred prior to appointment.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	I have a speaker meeting organised by Ipsen in December 2023 related to kidney cancer where I will be presenting the real-world audit data on bone mets management in mRCCS which I was	12/23	10/23	12/23	Non - specific Declare and participate.



			involved in. I will receive speaker fees for this work.				
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Travel grants for conferences: Astellas, Bayer, EUSA, Ipsen, Janssen, Pfizer, Sanofi.  Astellas, Bayer, Janssen – Prostate. Sanofi - skin cancer. Pfizer - part funded to attend GU-ASCO 2019. Ipsen - related to RCC, sponsoring to go to ESMO 2023.	2014	09/23	Ongoing	Specific Declare and participate. Part funding to attend RCC conference is reasonable.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Advisory boards: Advanced Accelerator Applications, Merck, Regeneron, Sanofi. Meetings organised by Janssen & Merck in Nov. Both related to bladder cancer.	2014	09/23	Ongoing	Non-specific Declare and participate.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	I undertake private practice at Genesis Care, Bristol. My PP is about 5% of my clinical time. I predominantly see skin cancer pts. I haven't seen any pt with renal cancer yet privately.	2018	09/23	Ongoing	Non-specific Declare and participate.

Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct, non-financial professional and personal	Member of Clinical Oncology Quality Improvement and Audit Committee (COQIAC); Royal College of Radiologists.	07/23	09/23	Ongoing	Non-specific Declare and participate.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct, non-financial professional and personal	Clinical expert advisor for PenTAG evidence review group for NICE renal cell carcinoma pathways pilot appraisal of the clinical and cost effectiveness of treatments. This is an unpaid role. I haven't received any honoraria/ claimed expenses so far.	04/23	09/23	Ongoing	Specific Declare and participate.  Open declaration is sufficient mitigation.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Indirect-financial and Direct-non-financial professional and personal	Received Institutional research grant from Regeneron/ Sanofi for UK multicenter study in advanced basal cell carcinoma. The monies are going to the Investigator led trials unit. This is a single arm open labelled study looking at efficacy of Cemiplimab in patients with advanced basal cell carcinoma.	10/23	09/23	Ongoing	Non-specific Declare and participate.

Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct, non-financial professional and personal	Appointed as Clinical Reference group member of National Kidney cancer audit, representing RCR.	09/23	09/23	Ongoing	Non-specific Declare and participate.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Consultant Clinical Oncologist, University Hospitals Bristol and Weston NHS Foundation Trust	2014	10/23	Ongoing	Declare and participate. Salaried employment in NHS.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Clinical Director, University Hospitals Bristol and Weston NHS Foundation Trust	2022	10/23	Ongoing	Declare and participate. Salaried employment in NHS.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Speaker meeting on 17 July 2024, sponsored by BMS, where I will be talking about updated checkmate 214 and 9ER data.	07/24	07/24	07/24	Non-specific Declare and participate.  Not in scope. We are not reviewing the evidence around pharmaceuticals in this guideline.(We will be incorporating TAs instead to address the scope questions on this topic.)

Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct, non-financial professional and personal	Appointed as a NIHR RDN National Specialty and Settings Lead for Cancer	06/24	07/24	Ongoing	Non-specific Declare and participate. Not specific to the scope of this guideline.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Ipsen is sponsoring my attending ESMO conference (registration, travel and accommodation).	09/24	08/24	09/24	Non-specific Declare and participate. Part funding to attend conference is reasonable.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Recording to discuss real world mRCC audit data on behalf of the UK renal oncology collaborative (UKROC) – facilitated by Merck.	09/24	09/24	09/24	Non-specific Declare and participate. Not specific to the scope of this guideline.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	Taking part in a speaker meeting to discuss management of mRCC. I will be a discussant of the cases on metastatic renal cancer presented by others. I will personally receive honorarium. The meeting is sponsored by Eisai.	01/25	01/25	01/25	Specific Declare and participate. Open declaration is sufficient mitigation.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	I am speaking on the benefit of UK real world data in mRCC and how	03/25	03/25	03/25	Non-specific Declare and participate.

	expertise beyond tertiary care)		the UK RCOC group was started at a meeting sponsored by Ipsen.  I will receive a speaker's fee.				Not specific to the scope of this guideline.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct-financial	I have done a speaker meeting for BMS and I have had speaker fees paid to me. I have discussed a case study of a patient on Ipilimumab/Nivolumab in the meeting.	05/25	06/25	05/25	Specific Declare and participate  Whilst relevant to a Technology Appraisal being incorporated into this guideline the committee are not reviewing evidence for this drug.
Amarnath Challapalli	Committee member – Clinical Oncologist (general oncology expertise beyond tertiary care)	Direct, Non-financial professional and personal	Appointed as Royal College of Radiologists Clinical Oncology Learning Lead.	05/25	06/25	Ongoing	Non-specific Declare and participate.
Amy Clifford	Committee member – Clinical Oncologist (renal specific expertise in SABR)	Direct, Non-financial professional and personal	I have written a case study on setting up the renal SABR service at the Royal Free for the 'Getting it right first time' (GIRFT) kidney cancer initiative. This has not been included in the current published document but I am listed as an author on the guidelines.	07/23	09/23	Ongoing	Specific  Declare and participate.  Open declaration is sufficient mitigation.

Amy Clifford	Committee member – Clinical Oncologist (renal specific expertise in SABR)	Direct non- financial professional and personal	When the IROCK consortium open their European registry study on renal SABR later this year I will contribute patient outcome data to their study.	11/23	09/23	Ongoing	Specific  Declare and participate.  Study unlikely to publish before the guideline but will be kept under review during development phase.
Amy Clifford	Committee member – Clinical Oncologist (renal specific expertise in SABR)	Direct non- financial professional and personal	I have undertaken a survey of UK oncologists experience of renal SABR which I intend to publish.	07/23	09/23	Ongoing	Specific  Declare and participate.  Survey will not be included in the evidence base.
Amy Clifford	Committee member – Clinical Oncologist (renal specific expertise in SABR)	Direct non- financial professional and personal	I have co-authored an abstract of lessons learned from setting up the renal SABR service at the Royal Free which has been submitted to the upcoming SABR consortium conference.	08/23	09/23	Ongoing	Specific  Declare and participate.  Paper will not be included in the evidence base.
Amy Clifford	Committee member – Clinical Oncologist (renal specific expertise in SABR)	Direct-financial	Consultant Clinical Oncologist, Royal Free Hospital	09/21	10/23	Ongoing	Declare and participate.  Salaried employment in the NHS.
John Connolly	Committee member – Lay member	Nil	Nil	Nil	Nil	Nil	Nil

David Cullen	Committee member – Urology Cancer Nurse	Direct Financial	Clinical Nurse Specialist, Royal Free Hospital London NHS Foundation Trust	2014	11/23	Ongoing	Declare and participate. Salaried employment in the NHS
Stuart Evans	Committee member – Oncology Pharmacist	Direct-financial	Lead Cancer Pharmacist, Swansea Bay University Health Board	07/00	10/23	Ongoing	Declare and participate. Salaried employment in the NHS.
Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Trustee of Kidney Cancer UK	07/21	11/23	Ongoing	Specific Declare and partial exclusion  Can participate in discussion but excluded from decision making in response to Kidney Cancer UK consultation comments.  <b>Geraldine Fox, Committee member, was excluded from decision making in response to Kidney Cancer UK consultation comments at committee meeting 13 (day 1) on 19/11/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>

Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Member Kidney Cancer Accord	01/18	11/23	Ongoing	Non-specific Declare and participate.
Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Member of Steering Committee - PARTIAL Trial	10/22	11/23	Ongoing	Non-specific Declare and participate.
Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Member MultiMIBI Trial Steering Committee	04/23	11/23	Ongoing	Non-specific Declare and participate.
Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Member Digital Twin Assisted Surgery Project	11/23	11/23	Ongoing	Non-specific Declare and participate.
Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Kidney Cancer UK member	07/21	11/23	Ongoing	Non-specific Declare and participate.
Geraldine Fox	Committee member – Lay member	Direct-non- financial professional and personal	Joined NHS SABR Policy Working Group looking at development of a policy for localised kidney cancer patients who are not suitable for nephrectomy.	12/23	12/23	Ongoing	Non-specific Declare and participate.



Geraldine Fox	Committee member – Lay member	Direct Financial	Paid attendance at Renal cell carcinoma event in London: 'RCC Med Ed (Educational Meeting MDT Key Conversations in Renal Cell Carcinoma: Collaboration' to talk about experience with kidney cancer.	03/24	12/23	03/24	Non-specific Declare and participate.
Geraldine Fox	Committee member – Lay member	Direct non-financial professional and personal	Member of the National Kidney Cancer Audit Clinical Reference Group.  No honorarium, expenses or other remuneration received.	09/23	08/24	Ongoing	Non-specific Declare and participate
Geraldine Fox	Committee member – Lay member	Direct non-financial professional and personal	Co-author on a report on 10 years of patient surveys carried out on a yearly basis by Kidney Cancer UK.  Rossi SH, Fox G, Packer M, Greaves A, Tran M, Charnley N, Oades G, Boleti E, Stewart GD. <a href="#">A decade long insight into patient views on kidney cancer care delivery</a> . BJU Int. 2025 Feb;135(2):243-245. doi: 10.1111/bju.16530. Epub	01/25	03/25		Non-specific Declare and participate

			2024 Sep 12. PMID: 39263957; PMCID: PMC11745991.				
Geraldine Fox	Committee member – Lay member	Direct non- financial professional and personal	Research study application, Patient co- investigator - Shared Decision Making focusing on Small Renal Masses  I will not receive payment for this work.	02/25	03/25	Ongoing	Non-specific  Declare and participate
Geraldine Fox	Committee member – Lay member	Direct non- financial professional and personal	PPI on research project: INVestigation Of Immune Priming Interventions in Kidney CancEr (INVOKE) looking at improving non- surgical treatments and developing better tools to monitor small kidney tumours  I will not receive payment for this work.	03/25	03/25	Ongoing	Non-specific  Declare and participate
Geraldine Fox	Committee member – Lay member	Direct non- financial professional and personal	Involved with reviewing the documentation and recommendations for this study but did not act as patient representative:  <a href="#">Harrison, Hannah;</a> <a href="#">Stewart, Grant D; Usher-</a>	02/23	04/25		Specific  Declare and participate  Study is included in the evidence base for RQ1 (information needs) however member's role

			<a href="#">Smith, Juliet A (2023) Patient experience of follow-up after surgery for kidney cancer: a focus group study.</a> BJU international 132(1): 47-55  Received no payment or honorarium for this work.				was limited to reviewing documentation.
Geraldine Fox	Committee member – Lay member	Direct non-financial professional and personal	Co-author: Bernstein DE, Warren H, Santiapillai J, Fox G, Wildgoose WH, Stewart GD, et al. A modified Delphi consensus statement on the role of biopsy in small renal masses. BJUI Compass. 2025; 6(4):e70018. <a href="https://doi.org/10.1002/bco.2.70018">https://doi.org/10.1002/bco.2.70018</a>	03/25	05/25		Specific Declare and participate Interest is specific to RQ2b on biopsy but study was not included in the evidence base.
Ana Filipa Goncalves Semedo	Vice Chair and Committee member – Oncology Cancer Nurse	Direct-financial	Lead Clinical Nurse Specialist Uro-Oncology, The Royal Marsden Hospital NHS Trust Foundation Trust	07/23	10/23	Ongoing	Declare and participate. Salaried position in NHS.
Ana Filipa Goncalves Semedo	Vice Chair and Committee member – Oncology Cancer Nurse	Direct-financial	Lead Nurse for Renal/Kidney Cancer, Royal Free Hospital NHS Trust Foundation Trust	11/21	10/23	06/23	Declare and participate. Previous salaried position in NHS.

Ana Filipa Goncalves Semedo	Vice Chair and Committee member – Oncology Cancer Nurse	Direct -non-financial professional and personal	Member of the Renal cell cancer (RCC) steering committee for the Ipsen Educational Exchange (IEE) Nurses Promotional Meeting	12/23	12/23	05/24	Declare and participate.
Ana Filipa Goncalves Semedo	Vice Chair and Committee member – Oncology Cancer Nurse	Direct -non-financial professional and personal	Panel member for the European Association of Urology Nurses (EAUN) poster review committee.	03/26	10/25		Non-specific Declare and participate
Ana Filipa Goncalves Semedo	Vice Chair and Committee member – Oncology Cancer Nurse	Direct -non-financial professional and personal	Collaboration with the Portuguese Institute of Oncology on an implementation project of the oncology nurse role in Portugal. This includes documenting and analysing an existing model.		10/25		Non-specific Declare and participate
Fayiza Habeeb	Committee member – Advanced Nurse Practitioner	Direct financial	Lead Nurse Practitioner-Metastatic Uro-oncology, Royal Free Hospital NHS, London	02/17	11/23	Ongoing	Declare and participate. Salaried employment in the NHS
Fayiza Habeeb	Committee member – Advanced Nurse Practitioner	Direct financial	Speaker fees, travel and accommodation received from Bayer both for presenting topics -	May 2024	03/24	May 2024	Non-specific Declare and participate.

			<p>1. adverse effects management with ARI drugs in prostate cancer</p> <p>2. Factors influencing treatment decisions in metastatic hormone sensitive prostate cancer</p>				
Fayiza Habeeb	Committee member – Advanced Nurse Practitioner	Direct financial	<p>Speaker Honorarium and travel expense from Bayer pharma -</p> <p>Topic - "Patient selection and treatment decision in non- metastatic castrate resistant prostate cancer".</p>	03/25	03/25	03/25	Non-specific Declare and participate.
David Mole	Committee member – Co-opted Nephrologist	Direct financial	Professor of Renal Medicine, University of Oxford and Honorary Consultant Nephrologist, Oxford Renal Unit & Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust	2016	11/23	Ongoing	Declare and participate. Salaried employment in the NHS
David Mole	Committee member – Co-opted Nephrologist	Direct financial	My Research is currently funded through a collaborative grant from King Abdulaziz University in Saudi Arabia to the	2015	11/23	Ongoing	Non-specific Declare and participate.

			University of Oxford. I am also a co-applicant on a research grant from the Royal Society.				
David Mole	Committee member – Co-opted Nephrologist	Direct financial	I have open applications for research funding from the Medical Research Council in the UK and from the VHL Alliance in the US	09/23	11/23	Ongoing	Non-specific Declare and participate.
Vishal Patil	Committee member – Co-opted Anaesthetist	Direct Financial	Consultant Anaesthesiologist at Cambridge University Hospitals NHS Foundation Trust	2004	11/23	Ongoing	Declare and participate. Salaried employment in the NHS
Vishal Patil	Committee member – Co-opted Anaesthetist	Direct Financial	Private practice as Consultant Anaesthesiologist	2004	11/23	Ongoing	Declare and participate.
Vishal Patil	Committee member – Co-opted Anaesthetist	Direct-non- financial professional and personal	Author of Guidelines for Provision of Anaesthesia Service, Chapter on Perioperative Care published by Royal College of Anaesthetists (RCoA)	2015	11/23	Ongoing	Specific Declare and participate.
Vishal Patil	Committee member – Co-opted Anaesthetist	Direct-non- financial professional and personal	Anaesthesia Clinical Services Accreditation (ACSA) reviewer for the	2017	11/23	Ongoing	Non-specific Declare and participate.

			Royal College of Anaesthetists				
Vishal Patil	Committee member – Co-opted Anaesthetist	Direct-non-financial professional and personal	Co-opted member of Anaesthesia Clinical Services Accreditation (ACSA) Committee for the Royal College of Anaesthetists	2023	11/23	Ongoing	Non-specific Declare and participate.
Elena Pizzo	Expert Witness	Direct- financial	Professor of Health Economics at the University College London.	10/23	04/25	Ongoing	Declare and participate This witness is providing expert advice to the committee and will not be contributing to recommendation drafting or decision making.
Elena Pizzo	Expert Witness	Direct-non-financial professional and personal	I am the senior author of a paper on the "Cost-utility of 99m Tc-SestaMIBI SPECT/CT in the diagnosis of kidney tumours" that will be included in the evidence base.	09/24	04/25	Ongoing	Declare and participate This witness is providing expert advice to the committee and will not be contributing to recommendation drafting or decision making.
Ankit Rao	Committee member – Medical Oncologist	Direct Financial	Consultant Medical Oncologist, Royal Free Hospital London NHS Foundation Trust	07/23	11/23	Ongoing	Declare and participate. Salaried employment in the NHS

Sandeep Singh Randhawa	Committee member – General Practitioner	Direct-financial	GP / Partner Modality Partnership & LL	2011	09/23	Ongoing	Declare and participate. Salaried employment in not-for-profit organisation providing NHS services.
Sandeep Singh Randhawa	Committee member – General Practitioner	Direct-financial	Senior Clinical Tutor University of Birmingham	2011	09/23	Ongoing	Declare and participate. Salaried employment in the NHS.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid section editor of British Journal of Urology International	04/20	07/23	01/25	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid consultancy by MSD on future medical education events	05/23	07/23	05/23	Specific Declare and participate. Interest has ceased, and member has agreed not undertake any paid roles for the duration of guideline.



Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid consultancy by Claruvate on current developments in kidney cancer	03/23	07/23	03/23	Specific  Declare and participate.  Interest has ceased, and member has agreed not undertake any paid roles for the duration of guideline.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Royalties as editor of chapter in Davidson's Principals and Practice of Medicine	05/18	07/23	Ongoing	Non-specific  Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non- financial professional and personal	Trustee of Kidney Cancer UK	04/20	07/23	Ongoing	Specific  Declare and partial exclusion from scoping meeting 3 and post- consultation committee meeting.  Can participate in discussion but excluded from decision making in response to Kidney Cancer UK consultation comments.  <b>Grant Stewart, Committee member, was excluded from decision making relating to Kidney Cancer UK consultation comments at scoping</b>

							<b>meeting 3 on 10/10/23, committee meeting 13 (day 1) on 19/11/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal	Chair of Science and Education Committee and Trustee of The Urology Foundation	04/18	07/23	04/23	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid employment by University of Cambridge as Professor of Surgical Oncology	02/20	07/23	Ongoing	Declare and participate. Salaried employment in not-for-profit organisation.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Clinical Lead (Urology) of the National Kidney Cancer Audit. I receive 1PA for this activity.	04/23	07/23	Ongoing	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal	Chair of GIRFT Kidney Cancer Academy Document.	04/22	07/23	Ongoing	Specific Declare and participate. .

Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal	Published widely on all aspects of kidney cancer, especially screening and predictive tools for RCC follow-up as well as translational work on RCC trials and neoadjuvant clinical trials  Funding bodies are NIHR, CRUK and YCR	2005	07/23	Ongoing	Specific Declare and participate.  Interest will be kept under review depending on the matter under consideration.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	MSD - honorarium for development and delivery of a physician education event on 06/03/24. Talk topic is an overview of the management of localised kidney cancer.	11/23	10/23	03/24	Specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	AstraZeneca - educational grant for investigator initiated trial (WIRE - ( <b>W</b> indow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in <b>RE</b> nal cell cancer) that I am the chief investigator of.	06/20	10/23	Ongoing	Specific Declare and participate. .

			Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).				
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	<p>AstraZeneca - educational grant for investigator initiated trial RAMPART that I am the translational lead of.</p> <p>Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).</p>	10/18	07/23	Ongoing	Specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	<p>I am chief investigator of Cancer Research UK funding for the TransRAMPART: Renal Adjuvant Multiple Arm Randomised Trial - Translational Research (A28690).</p> <p>Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).</p>	8/19	01/24	Ongoing	Specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and	Chief investigator of the Yorkshire Kidney Screening Trial - a	10/20	01/24	Ongoing	Non-specific Declare and participate.

		personal and indirect-financial	<p>Yorkshire Lung Screening Trial substudy. Funding from Yorkshire Cancer Research.</p> <p>Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).</p>				
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	<p>Co-investigator on the NIHR Research for Patient Benefit (RfPB) Programme grant: Risk Stratified Surveillance after Surgery for Kidney Cancer: Development, validation and feasibility testing of a New Prediction Tool to promote informed decision making.</p> <p>Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).</p>	01/24	01/24	Ongoing	Specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	<p>Co-investigator on the EPSRC grant: Real-time Digital Twin Assisted Surgery.</p> <p>Payments for this have gone to my institutions (University of Cambridge</p>	07/23	01/24	Ongoing	Specific Declare and participate.

			and CUH NHS Foundation Trust).				
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	Co-investigator on Cancer Research UK funded project - Comprehensive genomic analysis of tumour and host interactions in the genesis of kidney cancer.  Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).	09/22	01/24	Ongoing	Specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal and indirect-financial	Co-investigator on the HTA funded PARTIAL study – a randomised trial of the clinical and cost effectiveness of PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma.  Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).	02/22	01/24	Ongoing	Specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and	Co-lead for the Urological Malignancies Virtual Institute at the CRUK Cambridge Centre. CRUK	01/20	01/24	Ongoing	Specific Declare and partial exclusion

		personal and indirect-financial	provide funding for staff and consumables.  Payments for this have gone to my institutions (University of Cambridge and CUH NHS Foundation Trust).				<p>Declare and partial exclusion from post-consultation committee meeting.</p> <p>Can participate in discussion but excluded from decision making in response to Urological Malignancies Programme, University of Cambridge consultation comments.</p> <p><b>Grant Stewart, Committee member, was excluded from decision making relating to Urological Malignancies Programme, University of Cambridge consultation comments at committee meeting 13 (day 1) on 19/11/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b></p>
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial	Laird A, Choy KC, Delaney H, Cutress ML, O'Connor KM, Tolley DA, McNeill SA, Stewart GD, Riddick	06/24	06/24	03/20	<p>Specific</p> <p>Declare and partial exclusion.</p>

		professional and personal	AC. Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma. World J Urol. 2015 Jan;33(1):25-32. doi: 10.1007/s00345-014-1280-y. Epub 2014 Mar 20. PMID: 24647880.				Study included in the evidence base for RQ4a looking at nephrectomy and SABR for locally advanced RCC. The paper is broadly in line with other, larger studies in this area and the committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.  <b>Grant Stewart, Committee member, was excluded from recommendation drafting at committee meeting 6 on 18/09/24, meeting 12 (day 2) on 13/06/25 and meeting 13 (day 1) on 19/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal	Usher-Smith, J.A., Li, L., Roberts, L., Harrison, H., Rossi, S.H., Sharp, S.J., Coupland, C., Hippisley-Cox, J., Griffin, S.J., Klatte, T. and Stewart, G.D. (2022), Risk models for recurrence and survival		08/24		Specific  Declare and partial exclusion  Study included in the evidence base for RQ2c part 1 (prognostic models



			after kidney cancer: a systematic review. BJU Int, 130: 562-579. <a href="https://doi.org/10.1111/bju.15673">https://doi.org/10.1111/bju.15673</a>				for non- metastatic kidney cancer) however committee member's expertise is essential to this discussion.  Participate in discussion but withdraw for drafting recommendations.  <b>Grant Stewart, Committee member, was excluded from recommendation drafting on risk models for non-metastatic RCC at committee meeting 8 on 12/12/24 and meeting as (day 2) on 13/06/25, due to a declared conflict of interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct -non-financial professional and personal	Author on papers about Leibovich prediction model for people with non-metastatic KC):  <a href="#">Vasudev, Naveen S, Hutchinson, Michelle, Trainor, Sebastian et al. (2020) UK Multicenter Prospective Evaluation of the Leibovich Score in</a>	Various	10/24		Specific  Declare and partial exclusion  Studies included in the evidence base for RQ2c part 1 (non-metastatic prediction models) however committee member's

			<p><a href="#">Localized Renal Cell Carcinoma: Performance has Altered Over Time.</a> Urology 136: 162-168</p> <p><a href="#">Oza, Bhavna, Eisen, Tim, Frangou, Eleni et al. (2022) External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.</a> Journal of clinical oncology: official journal of the American Society of Clinical Oncology 40(16): 1772-1782</p> <p><a href="#">Um, In Hwa, Scott-Hayward, Lindesay, Mackenzie, Monique et al. (2020) Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma.</a> Journal of pathology informatics 11: 35</p>				<p>expertise is essential to this discussion.</p> <p>Participate in discussion but withdraw for drafting recommendations*.</p> <p>* Conflicted for VENUSS tool and being an author on a related systematic review as well so full exclusion from recommendation drafting.</p> <p><b>Grant Stewart, Committee member, was excluded from recommendation drafting on risk models for non-metastatic RCC at committee meeting 8 on 12/12/24 and meeting as (day 2) on 13/06/25, due to a declared conflict of interest, in line with NICE's policy.</b></p>
--	--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Grant Stewart	Committee member - Topic Adviser	Direct -non- financial professional and personal	Klatte, T., Gallagher, K.M., Afferi, L. <i>et al.</i> The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. <i>BMC Med</i> <b>17</b> , 182 (2019). <a href="https://doi.org/10.1186/s12916-019-1419-1">https://doi.org/10.1186/s12916-019-1419-1</a>	2019	10/24	<p>Specific Declare and partial exclusion</p> <p>Study included in the evidence base for RQ2c part 1 (non-metastatic prediction models) however committee member's expertise is essential to this discussion.</p> <p>Participate in discussion but withdraw for drafting recommendations*.</p> <p>*Conflicted for Leibovich tool and being an author on a related systematic review as well so full exclusion from recommendation drafting.</p> <p><b>Grant Stewart, Committee member, was excluded from recommendation drafting on risk models for non- metastatic RCC at committee meeting 8 on 12/12/24 and meeting 12 (day 2) on 13/06/25, due to a declared conflict of</b></p>
---------------	-------------------------------------	-----------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------	-------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

							<b>interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct -non- financial professional and personal	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel P; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.); <a href="#">Scandinavian journal of urology; 2019; vol. 53 (no. 1); 14-20</a>	12/2024	12/2024		<p>Specific</p> <p>Declare and partial exclusion</p> <p>Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.</p> <p>Participate in discussion but withdraw for drafting recommendations.</p> <p><b>Grant Stewart, Committee member, was excluded from recommendation drafting on follow-up at committee meeting 10 (day 2) on 26/03/25, committee meeting 12 (day 1) on 03/06/2025,committee meeting 12 (day 2) on 13/06/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of</b></p>

							<b>interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct -non- financial professional and personal	Dabestani, Saeed; Beisland, Christian; Stewart, Grant D; Bensalah, Karim; Gudmundsson, Eirikur; Lam, Thomas B; Gietzmann, William; Zakikhani, Paimaun; Marconi, Lorenzo; Fernandez-Pello, Sergio; Monagas, Serenella; Williams, Samuel Paul; Torbrand, Christian; Powles, Thomas; Van Werkhoven, Erik; Meijer, Richard; Volpe, Alessandro; Staehler, Michael; Ljungberg, Borje; Bex, Axel; Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).; <a href="#">European urology; 2019; vol. 75 (no. 2); 261-264</a>	12/2024	12/2024		<p>Specific Declare and partial exclusion</p> <p>Study included in the evidence base for RQ5b on follow up however committee member's expertise is essential to this discussion.</p> <p>Participate in discussion but withdraw for drafting recommendations.</p> <p><b>Grant Stewart, Committee member, was excluded from recommendation drafting on follow-up at committee meeting 10 (day 2) on 26/03/25, committee meeting 12 (day 1) on 03/06/2025,committee meeting 12 (day 2) on 13/06/25, and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of</b></p>

							<b>interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Indirect financial and direct non- financial professional and personal	Chief Investigator of TACTICAL1 trial a pilot RCT of screening for serious abdominal conditions. This includes Kidney Cancer. Funded by YCR.	11/24	12/12	04/26	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Indirect financial and direct non- financial professional and personal	Co-I of MANIFEST trial, biomarkers for immunotherapy in cancer. This will include Kidney Cancer patients. MRC funded.	08/24	12/12	Ongoing	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid consultancy for Evinova on the use of patient reported symptoms in cancer. Kidney Cancer patients were discussed as examples.	02/24	12/12	10/24	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid consultancy for Quirin on urinary biomarkers in bladder cancer. This not related to Kidney Cancer.	11/24	12/12	Ongoing	Non-specific Declare and participate.
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Paid Associate Editor of British Journal of Urology International	01/25	01/25	Ongoing	Non-specific Declare and participate
Grant Stewart	Committee member - Topic Adviser	Direct non- financial	Rossi SH, Fox G, Packer M, Greaves A, Tran M, Charnley N, Oades G,	09/24	03/25		Non-specific Declare and participate

		professional and personal	Boleti E, Stewart GD. <a href="#">A decade long insight into patient views on kidney cancer care delivery</a> . BJU Int. 2025 Feb;135(2):243-245. doi: 10.1111/bju.16530. Epub 2024 Sep 12. PMID: 39263957; PMCID: PMC11745991.				
Grant Stewart	Committee member - Topic Adviser	Direct non-financial professional and personal	Harrison, H., Stewart, G.D. and Usher-Smith, J.A. (2023), <a href="#">Patient experience of follow-up after surgery for kidney cancer: a focus group study</a> . BJU Int, 132: 47-55. <a href="https://doi.org/10.1111/bju.15982">https://doi.org/10.1111/bju.15982</a>	2023	04/25		<p>Specific</p> <p>Declare and partial exclusion.</p> <p>Included study for RQ1 on information needs.</p> <p>Participate in discussion but withdraw from drafting recommendations.</p> <p><b>Grant Stewart, Committee member, was excluded from recommendation drafting on information needs at committee meeting 11 (day 2) on 08/05/25, committee meeting 12 (day 1) on 03/06/25, committee meeting 12 (day 2) on 13/06/25, committee meeting 13 (day 1) on</b></p>

							<b>19/11/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct non-financial professional and personal	Ranieri, V., Warren, H., Florez, I., Neves, J.B., Walkden, M., Bernstein, D.E., Santiapillai, J., Williams, N., Wildgoose, W.H., Patki, P., Stewart, G.D., Kinsella, N., Pizzo, E., Barod, R., Bex, A., Mumtaz, F., El-Sheikh, S., Gurusamy, K. and Tran, M.G.B. (2024), Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. BJU Int, 134: 796-804. <a href="https://doi.org/10.1111/bju.16470">https://doi.org/10.1111/bju.16470</a>	2024	04/25		<p>Specific</p> <p>Declare and partial exclusion.</p> <p>Included study for RQ1 on information needs.</p> <p>Participate in discussion but withdraw from drafting recommendations. (Full exclusion from recommendation drafting due to having 2 included studies for this review that spanned multiple stages of the treatment pathway.)</p> <p><b>Grant Stewart, Committee member, was excluded from recommendation drafting on information needs at committee meeting 11 (day 2) on 08/05/25, committee meeting 12 (day 2) on 03/06/25, committee meeting 12 (day 2) on</b></p>



							<b>13/06/25,meeting 13 (day 1) on 19/11/25 and committee meeting 13 (day 2) on 25/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Renal Lab Europe: I will be part of a think tank on unresolved challenges in renal cell carcinoma management by engaging leading European experts. Funded by Ipsen. Honorarium will be provided.	10/25	05/25	Ongoing	Non-specific Declare and participate
Grant Stewart	Committee member - Topic Adviser	Direct-financial	Member of the King Hussein Cancer Research Award Evaluation Committee. An honorarium will be provided.	05/25	05/25	Ongoing	Non-specific Declare and participate
Grant Stewart	Committee member - Topic Adviser	Direct non-financial professional and personal	Co-author: Bernstein DE, Warren H, Santiapillai J, Fox G, Wildgoose WH, Stewart GD, et al. A modified Delphi consensus statement on the role of biopsy in small renal masses. BJUI Compass. 2025; 6(4):e70018.	03/25	05/25		Specific Declare and participate Interest is specific to RQ2b on biopsy but study was not included in the evidence base.

			<a href="https://doi.org/10.1002/bco.2.70018">https://doi.org/10.1002/bco.2.70018</a>				
Maxine Tran	Committee member – Urological Surgeon	Direct-financial	Paid consultancy for speaking engagements, participation on advisory board on understanding the MDT process, VHL advisory board and developing a MDT decision (MSD). This is related to kidney cancer; it was a clinical standpoint on the current management of VHL patients (discussed at MDT) and the potential role and impact that Belzutifan might have on these patients.	04/22	09/23	08/23	Non-specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Direct-financial	Paid consultancy for speaking engagements at educational meeting, advisory board and webcast on evidence for ablation kidney cancer (Boston Scientific Inc).	05/23	09/23	08/23	Specific Declare and participate. Open declaration is sufficient mitigation
Maxine Tran	Committee member – Urological Surgeon	Direct-financial	Paid clinical expert on invited cases for the Parliamentary Health Service Ombudsman and also the Public Service	03/22	09/23	Ongoing	Non-specific Declare and participate.

			Ombudsman of Wales and also of Ireland .  Sometimes the case involves kidney cancer but there have been some general urology and surgical cases.				
Maxine Tran	Committee member – Urological Surgeon	Non-financial professional and personal	European Association of Urology Kidney Cancer Guideline Panel member.	07/23	09/23	Ongoing	Non-specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Non-financial professional and personal	Trustee for Kidney Cancer UK charity.	02/16	09/23	ongoing	Specific Declare and partial exclusion from scoping meeting 3 and post-consultation committee meeting  Can participate in discussion but excluded from decision making in response to Kidney Cancer UK consultation comments.  <b>Maxine Tran, Committee member, was excluded from decision making relating to Kidney Cancer UK consultation comments at scoping meeting 3 on 10/10/23 and meeting 13 (day 1)</b>

							<b>on 19/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Maxine Tran	Committee member – Urological Surgeon	Non-financial professional and personal	Trustee for British Journal of Urology International.	07/23	09/23	ongoing	Non-specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Non-financial professional and personal	Governor on the Royal Free NHS Foundation Trust's council of Governors.	06/20	09/23	ongoing	Non-specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Indirect-financial and direct non-financial professional and personal	Chief investigator on NIHR funded feasibility study comparing cryoablation and robot assisted partial nephrectomy for small renal masses (NEST). Funding goes to my employer/institution. <a href="#">Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy - PubMed (nih.gov)</a>	05/19	09/23	05/22	Specific Declare and participate Study included in the evidence base for RQ3b for completeness however trial is a very small feasibility study and forms a very small part of the evidence base.

Maxine Tran	Committee member – Urological Surgeon	Indirect-financial and direct non- financial professional and personal	Chief investigator on NIHR funded (IFIT-B): Identifying the facilitators and barriers to implementation of tumour biopsy in the diagnostic pathway for small renal masses.  Funding goes to my employer/institution.	02/20	09/23	10/22	Specific Declare and participate. .
Maxine Tran	Committee member – Urological Surgeon	Direct non- financial professional and personal	Ranieri, V., Warren, H., Florez, I., Neves, J.B., Walkden, M., Bernstein, D.E., Santiapillai, J., Williams, N., Wildgoose, W.H., Patki, P., Stewart, G.D., Kinsella, N., Pizzo, E., Barod, R., Bex, A., Mumtaz, F., El-Sheikh, S., Gurusamy, K. and Tran, M.G.B. (2024), <a href="#">Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses</a> . BJU Int, 134: 796-804. <a href="https://doi.org/10.1111/bju.16470">https://doi.org/10.1111/bju.16470</a>	2024	04/25		Specific Declare and partial exclusion.  Included study for RQ1 on communication.  Participate in discussion but withdraw from drafting recommendations about information to be provided about biopsy. Able to draft recommendations on information to be provided at other stages of the treatment pathway.  <b>Maxine Tran, Committee member, was excluded from recommendation drafting on information to be provided about biopsy at committee meeting 12 (day 2) on 03/06/25 and</b>

							<b>committee meeting 13 (day 1) on 19/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Maxine Tran	Committee member – Urological Surgeon	Indirect-financial and direct non-financial professional and personal	Chief investigator on NIHR funded study: <a href="#">A MULTI-centre feasibility study to assess the use of 99m Tc-SestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)</a> .  Funding goes to my employer/institution.	09/22	09/23	08/24	Specific Declare and participate. Interest is specific to RQ2a part 2 (additional imaging tests for differentiating renal masses) however study is not included in the evidence base.
Maxine Tran	Committee member – Urological Surgeon	Direct -non-financial professional and personal	Warren H, Tran MGB. <a href="#">99mTc-sestamibi SPECT/CT-the jury is still out!</a> Transl Androl Urol. 2024 Jun 30;13(6):1053-1055. doi: 10.21037/tau-23-623. Epub 2024 May 13. PMID: 38983466; PMCID: PMC11228679.	05/24	02/25		Specific Declare and participate. Interest is specific to RQ2a part 2 (additional imaging tests for differentiating renal masses) but content was not deemed to prejudice the committee member from approaching the evidence objectively.

							Interest will be kept under review depending on the matter under consideration.
Maxine Tran	Committee member – Urological Surgeon	Direct -non- financial professional and personal	Warren H, Wagner T, Gorin MA, Rowe S, Holman BF, Pencharz D, El-Sheikh S, Barod R, Patki P, Mumtaz F, Bex A, Kasivisvanathan V, Moore CM, Campaign N, Cartledge J, Scarsbrook A, Hassan F, O'Brien TS, Stewart GD, Mendichovszky I, Dizdarevic S, Alanbuki A, Wildgoose WH, Wah T, Vindrola-Padros C, Pizzo E, Dehbi HM, Lorgelly P, Gurusamy K, Emberton M, Tran MGB. <a href="#">Protocol for a MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)</a> . BMJ Open. 2023 Jan 24;13(1):e067496. doi: 10.1136/bmjopen-2022- 067496. PMID: 36693694; PMCID: PMC9884914.	01/24	02/25		Specific  Declare and participate.  Interest is specific to RQ2a part 2 (additional imaging tests for differentiating renal masses) but study protocol not included in the evidence base and results of study are not published.

Maxine Tran	Committee member – Urological Surgeon	Direct non- financial professional and personal	Author on an unpublished paper: A multi-centre feasibility study and cost effectiveness analysis to compare the outcomes of 99m Tc-SestaMIBI SPECT/CT, biopsy or empiric surgery in the diagnosis of kidney tumours		05/25		Specific  Declare and partial exclusion.  Included study for RQ2b on biopsy.  Participate in discussion but withdraw from recommendation drafting.  <b>Maxine Tran, Committee member, was excluded from recommendation drafting on biopsy at committee meeting 12 (day 2) on 03/06/25 and committee meeting 13 (day 1) on 19/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Maxine Tran	Committee member – Urological Surgeon	Indirect - financial	My husband is an equity partner at Close Brother's private equity Ltd and some of their investment portfolio companies are in the healthcare sector (e.g Dental practices, cataract surgery), none are pertaining to kidney cancer.	08/22	09/23	ongoing	Non-specific  Declare and participate.



Maxine Tran	Committee member – Urological Surgeon	Direct Financial	Professor of Urology at UCL and honorary consultant urological surgeon at the Royal Free Hospital	09/15	04/24	Ongoing	Declare and participate. Salaried position in NHS
Maxine Tran	Committee member – Urological Surgeon	Indirect financial and direct -non-financial professional and personal	I have published opinion pieces, basic and translational research in kidney cancer, including the use of novel diagnostic imaging and clinical trials in kidney cancer. My organisation received research funding from Kidney Cancer UK, Facing up to Kidney Cancer, CRUK, MRC, St Peter's Trust, NIHR, and the Royal Free Charity.	2007	04/24	Ongoing	Specific Declare and participate. Interest will be kept under review depending on the matter under consideration.
Maxine Tran	Committee member – Urological Surgeon	Indirect financial and direct non-financial professional and personal	Ongoing discussions with Boston Scientific in regard to potential funding for a trial to compare the effectiveness of cryoablation to partial nephrectomy. This is follow up to the NEST feasibility study directly relevant to the kidney cancer guideline.	09/23	04/24	Ongoing	Specific Declare and participate. This study will not be completed until after we publish.

			6-year study starting in Sept 24. Funding goes to organisation				
Maxine Tran	Committee member – Urological Surgeon	Direct -non-financial professional and personal	I am a peer reviewer for the NIHR, MRC, Royal College of Surgeons of England surgical fellowships, and The Urology Foundation.	09/23	04/24	Ongoing	Specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Direct -non-financial professional and personal	I contributed to the 'get it right first time' in Kidney Cancer initiative.	2023	04/24	2024	Specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Direct -non-financial professional and personal	I am on the clinical reference group for the National Kidney Cancer Audit	2023	04/24	Ongoing	Specific Declare and participate.
Maxine Tran	Committee member – Urological Surgeon	Direct -non-financial professional and personal	Member of the Programme Committee of the International Kidney Cancer Symposium: Europe	05/24	05/24	Ongoing	Non-specific Declare and participate.  Role on the committee is broad and not connected to anything specifically in scope for this guideline.
Maxine Tran	Committee member – Urological Surgeon	Direct non-financial professional and personal	Rossi SH, Fox G, Packer M, Greaves A, Tran M, Charnley N, Oades G, Boleti E, Stewart GD. <a href="#">A decade long insight into</a>	09/24	03/25		Non-specific Declare and participate

			<a href="#">patient views on kidney cancer care delivery</a> . BJU Int. 2025 Feb;135(2):243-245. doi: 10.1111/bju.16530. Epub 2024 Sep 12. PMID: 39263957; PMCID: PMC11745991.				
Maxine Tran	Committee member – Urological Surgeon	Direct-financial	I will be receiving honoraria from EISAI for attending a 'women leaders in RCC workshop' to talk about how patient advocacy impacts on care and research and attendance at an advisory board to provide advice on how to optimise the RCC patient pathway.	05/25	05/25	05/25	Non-Specific Declare and participate
Maxine Tran	Committee member – Urological Surgeon	Direct non-financial professional and personal	Co-author: Bernstein DE, Warren H, Santiapillai J, Fox G, Wildgoose WH, Stewart GD, et al. A modified Delphi consensus statement on the role of biopsy in small renal masses. BJUI Compass. 2025; 6(4):e70018. <a href="https://doi.org/10.1002/bco.2.70018">https://doi.org/10.1002/bco.2.70018</a>	03/25	05/25		Specific Declare and participate Interest is specific to RQ2b on biopsy but study was not included in the evidence base.

Maxine Tran	Committee member – Urological Surgeon	Direct-financial	Honorarium for advisory board from Telix; the manufacturers of Girentuximab (tracer used in nuclear imaging; funded the Zircon study).	10/25	11/25	10/25	Non-specific Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Direct-financial	Angiodynamics (Speaker Honorarium). Intermittent speaking/scientific advisory engagement on IRE in renal cancer, pancreas, and liver cancer	03/22	09/23	Ongoing	Non-specific Declare and participate. Interest is not currently within scope of this guideline.
Tze Min Wah	Committee member - Interventional Radiologist	Direct-financial	Boston Scientific (Speaker Honorarium). This one-off honorarium was related to talk on image guided renal ablation	05/23	09/23	06/23	Specific Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Direct-financial	Neuwave (Johnson & Johnson) Global Advisory Board. This work is not related to Kidney Cancer.	01/23	09/23	02/23	Non-specific Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Indirect-financial and direct non-financial professional and personal	Chief Investigator, CAIN Trial (HistoSonics, Industry Sponsored) NCT05432232: <a href="#">The HistoSonics System for Treatment of Primary</a>	03/23	09/23	Ongoing	Specific Declare and participate.

			<a href="#">Solid Renal Tumors Using Histotrips.</a> Monies got to my institution.				
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Honorary Professor of Interventional Radiology, Leeds Institute of Medical Research, University of Leeds.	08/22	09/23	Ongoing	Non-specific Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Elected member for Faculty Board, Royal College of Radiologists.	09/22	09/23	Ongoing	Non-specific Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Co-authored on numerous publications related to image guided renal ablation.	01/22	09/23	Ongoing	Specific Declare and participate. Interest will be kept under review depending on the matter under consideration
Tze Min Wah	Committee member - Interventional Radiologist	Indirect-financial and direct non-financial professional and personal	Co-applicant for NIHR MULTI-MIBI Study (ISRCTN12572202): <a href="#">MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours.</a> Monies go to my institution.	06/22	09/23	Ongoing	Specific Declare and participate.

Tze Min Wah	Committee member - Interventional Radiologist	Direct non- financial professional and personal	Author on an unpublished paper: A multi-centre feasibility study and cost effectiveness analysis to compare the outcomes of 99m Tc-SestaMIBI SPECT/CT, biopsy or empiric surgery in the diagnosis of kidney tumours		05/25		Specific  Declare and partial exclusion.  Included study for RQ2b on biopsy.  Participate in discussion but withdraw from recommendation drafting.
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Committee for NIHR Imaging Workforce Working Group.  Unpaid role with no honorarium/expenses.	04/23	09/23	Ongoing	Non-specific  Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Committee for CRG National Kidney Cancer Audit.  Unpaid role with no honorarium/expenses.	09/23	09/23	Ongoing	Non-specific  Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Member of the working group for GIRFT Renal Cancer Pathway.  Unpaid role with no honorarium/expenses.	07/22	09/23	06/23	Specific  Declare and participate.
Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Leading author for the <a href="#">Future Cancer UK: Histotripsy Evidence Document</a> for the DHSC (Published)	04/23	09/23	06/23	Specific  Declare and participate.  .

Tze Min Wah	Committee member - Interventional Radiologist	Non-financial professional and personal	Stakeholder representative for British Society of Interventional Radiology for NICE Clinical Guidelines.	08/23	09/23	Ongoing	<p>Specific Declare and partial exclusion from scoping meeting 3</p> <p>Can participate in discussion but excluded from decision making in response to BSIR scope consultation comments. New organisation stakeholder representative has been elected for draft guidance consultation.</p> <p><b>Tze Min Wah, Committee member, was excluded from decision making relating to BSIR scope consultation comments at scoping meeting 3 on 10/10/23 due to a declared conflict of interest, in line with NICE's policy.</b></p>

Tze Min Wah	Committee member - Interventional Radiologist	Indirect financial and direct non- financial professional and personal	I am part of the investigator team having discussion with Boston Scientific regarding the potential commercial funding a trial to compare the effectiveness of cryoablation to partial nephrectomy. This is follow -up to the NEST feasibility study. Directly relevant to the kidney cancer guideline.  6-year study starting in Sept 24 - Funding goes to organisation	09/24	05/24	Ongoing	Specific  Declare and participate.  Specific to RQ3b however this study will not be completed until after we publish.
Tze Min Wah	Committee member - Interventional Radiologist	Indirect financial and direct non- financial professional and personal	<a href="https://pubmed.ncbi.nlm.nih.gov/35384457/">Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma - https://pubmed.ncbi.nlm.nih.gov/35384457/v</a>	09/22	07/24		Specific  Declare and partial exclusion.  Included study for RQ3b on non-surgical interventions or active surveillance for localised RCC. Reasonable sized study which is an integral part of the evidence base.  Participate in discussion but withdraw from drafting recommendations.  <b>Tze Min Wah, Committee member, was excluded</b>



							<b>from drafting recommendations at committee meeting 5 on 17/07/24 and committee 13 (day 1) on 19/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Tze Min Wah	Committee member - Interventional Radiologist	Indirect financial and direct non-financial professional and personal	Chan VW, Lenton J, Smith J, Jagdev S, Ralph C, Vasudev N, Bhattarai S, Lewington A, Kimuli M, Cartledge J, Wah TM. Multimodal image-guided ablation on management of renal cancer in Von-Hippel-Lindau syndrome patients from 2004 to 2021 at a specialist centre: A longitudinal observational study. Eur J Surg Oncol. 2022 Mar;48(3):672-679. doi: 10.1016/j.ejso.2021.10.022. Epub 2021 Oct 28. PMID: 34728141.	2021	04/25		<p>Specific</p> <p>Declare and partial exclusion.</p> <p>Included study for RQ5c(ii) on interventions and follow-up for heritable RCC.</p> <p>Participate in discussion but withdraw from drafting recommendations.</p> <p><b>Tze Min Wah, Committee member, was excluded from recommendation drafting about interventions and follow-up for heritable RCC at committee meeting 11 (day 1) on 30/04/25, due to a declared conflict of interest, in line with NICE's policy.</b></p>

Tze Min Wah	Committee member - Interventional Radiologist	Indirect financial and direct non- financial professional and personal	Osman FH, Chan VW, Breen DJ, King A, Nielsen TK, Garnon J, Alcorn D, Lagerveld B, Graumann O, Keeley FX Jr, Walkden M, de Kerviler É, Wah TM. <a href="#">Oncological and Peri- Operative Outcomes of Cryoablation of Renal Cell Carcinoma for Patients with Hereditary RCC Diseases-An Analysis of European Multi-Centre Prospective EuRECA Registry</a> . Cancers (Basel). 2023 Jun 24;15(13):3322. doi: 10.3390/cancers15133322 . PMID: 37444432; PMCID: PMC10340367.	2023	04/25		Specific  Declare and partial exclusion.  Included study for RQ5c(ii) on interventions and follow- up for heritable RCC.  Participate in discussion but withdraw from drafting recommendations.  <b>Tze Min Wah, Committee member, was excluded from recommendation drafting about interventions and follow- up for heritable RCC at committee meeting 11 (day 1) on 30/04/25, due to a declared conflict of interest, in line with NICE's policy.</b>
Tze Min Wah	Committee member - Interventional Radiologist	Direct non- financial professional and personal	Co-author: Bernstein DE, Warren H, Santiapillai J, Fox G, Wildgoose WH, Stewart GD, et al. A modified Delphi consensus statement on the role of biopsy in small renal masses. BJUI Compass. 2025; 6(4):e70018.	03/25	05/25		Specific  Declare and participate  Interest is specific to RQ2b on biopsy but study was not included in the evidence base.

			<a href="https://doi.org/10.1002/bco.2.70018">https://doi.org/10.1002/bco.2.70018</a>				
James Whitworth	Committee member – Co-opted Clinical Geneticist	Direct Financial	Assistant Professor in Medical Genetics and Fellow – St Edmunds College, University of Cambridge	11/20	11/23	Ongoing	Declare and participate. Salaried employment
James Whitworth	Committee member – Co-opted Clinical Geneticist	Direct-non-financial professional and personal	Co-principal investigator on Early Detection of Hereditary Renal Cancer (RCC) study. Funded by Alliance for Cancer Early Detection. Project investigating the use of platelet analysis in detection of kidney cancer.	03/21	11/23	Ongoing	Specific Declare and participate.
James Whitworth	Committee member – Co-opted Clinical Geneticist	Direct-non-financial professional and personal	Investigator on the Molecular Pathology of Human Genetic Disease Study (IRAS project ID 50895). Multi-armed study investigation genetic causes of cancer and methods to detect cancers based on biological samples.	2014	11/23	Ongoing	Specific Declare and participate.
James Whitworth	Committee member – Co-opted Clinical Geneticist	Direct-non-financial professional and personal	Author on publications relating to genetic conditions causing renal cell carcinoma. Pubmed identifiers:	2022	11/23	Ongoing	Non-specific Declare and participate.

			PMID: 35184155 PMID: 35323939.				
James Whitworth	Committee member – Co-opted Clinical Geneticist	Direct-non-financial professional and personal	Participating in working group set up as part of the UK Cancer Genetics Group to formulate consensus guidance on surveillance in familial renal cell carcinoma without a diagnosed genetic cause	09/23	11/23	Ongoing	Specific Declare and participate.
James Whitworth	Committee member – Co-opted Clinical Geneticist	Indirect-financial and direct, non-financial professional and personal	Receipt of research grant from Urological Foundation to investigate urinary extracellular vesicles for early detection of renal cell carcinoma	07/22	11/23	Ongoing	Specific Declare and participate.
James Whitworth	Committee member – Co-opted Clinical Geneticist	Direct-non-financial professional and personal	Local Principal Investigator on study IRAS 352268, Non-interventional post-authorization study of belzutifan in adult patients with von Hippel-Lindau disease associated renal cell carcinoma, pancreatic neuroendocrine tumor and/or central nervous system	11/24	04/25	Ongoing	Specific Declare and participate Whilst relevant to a Technology Appraisal being incorporated into this guideline the committee are not reviewing evidence for this drug.

			hemangioblastoma. Funded by MSD.				
Sam Withey	Committee member – Diagnostic Radiologist	Direct-financial	<p>Private practice (Royal Marsden hospital).</p> <p>I report scans of patients with all cancer types, and therefore some of the patients do have kidney cancer.</p> <p>Approximately 85% of my work is NHS, 15% is private practice.</p> <p>I would estimate &lt;5% of all scans I report relate to kidney cancer.</p>	09/22	09/23	Ongoing	<p>Non-specific</p> <p>Declare and participate.</p> <p>Salaried sessional employment in the private health sector. Private practice is limited and non-specific to the scope of the guideline.</p>
Sam Withey	Committee member – Diagnostic Radiologist	Direct-financial	<p>Teleradiology reporting (DMC Radiology). I mainly report whole body MRI health screening. The work is not specifically related to kidney cancer, but a very small proportion of patients do get diagnosed with kidney cancer following the scan (I would estimate &lt;1-in-500 patients).</p>	08/22	09/23	Ongoing	<p>Non-specific</p> <p>Declare and participate.</p>

Sam Withey	Committee member – Diagnostic Radiologist	Direct -non-financial professional and personal	Committee member, British Society of Urogenital Radiology.  Unpaid role with no expenses or honorarium received.	02/23	09/23	Ongoing	Non-specific  Declare and participate.
Sam Withey	Committee member – Diagnostic Radiologist	Direct -non-financial professional and personal	Member of Renal Imaging Working Group, European Society of Urogenital Radiology.  Unpaid role with no expenses or honorarium received.	01/23	09/23	Ongoing	Non-specific  Declare and participate.
Rose Woodward	Committee member – Lay member	Direct Financial	Salaried role as part-time CEO of the charity Action Kidney Cancer	2015	11/23	Ongoing	Specific  Declare and partial exclusion  Can participate in discussion but excluded from decision making in response to Action Kidney Cancer consultation comments.  <b>Rose Woodward, Committee member, was excluded from decision making in response to Action Kidney Cancer consultation comments at committee meeting 13</b>

							<b>(day 1) on 19/11/25 due to a declared conflict of interest, in line with NICE's policy.</b>
Rose Woodward	Committee member – Lay member	Direct-non-financial professional and personal	Advocate/helping patients to negotiate the NHS system to access best possible care		11/23	Ongoing	Non-specific Declare and participate.
Rose Woodward	Committee member – Lay member	Direct-non-financial professional and personal	I am a patient representative for the International Kidney Cancer Coalition ( <a href="https://ikcc.org/research-initiatives/care1-pragmatic-clinical-trial/">https://ikcc.org/research-initiatives/care1-pragmatic-clinical-trial/</a> ) who are partners on the Management Group of the CARE1 Pragmatic Trial ( <a href="https://www.clinicaltrials.gov/study/NCT06364631">https://www.clinicaltrials.gov/study/NCT06364631</a> ) I do not receive any payment for this position.	04/24	12/25	Ongoing	Non-specific Declare and participate.
Rose Woodward	Committee member – Lay member	Direct-non-financial professional and personal	I am a member of the EAU Clinical Guidelines RCC Panel. My role has only recently become active as I have not been able to attend any meetings or training due to restrictions	03/25	12/25	Ongoing	Non-specific Declare and participate.

			on travel and face to face meetings since my kidney transplant last year. I did not play a role in the 2025 RCC Guideline. I do not receive any payment for the EAU position. ( <a href="https://uroweb.org/guidelines/renal-cell-carcinoma">https://uroweb.org/guidelines/renal-cell-carcinoma</a> )				
--	--	--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--